Edge Therapeutics Inc Report issue

For profit Phase 3
Founded: Berkeley Heights NJ United States (2009)
Status: Acquired by PDS Biotechnology Corp. (2019)

Organization Overview

First Clinical Trial
2013
NCT01893190
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

nimodipine (nimotop) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aneurysm (Phase 2)

Hemorrhage (Phase 3)

Intracranial Aneurysm (Phase 2)

Rupture (Phase 2)

Subarachnoid Hemorrhage (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1